Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Hepatobiliary disorders – page 17

  • 357 clinical trials
  • 141 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Hepatocellular carcinoma89Cholangiocarcinoma38Hepatic cirrhosis25Metabolic dysfunction-associated steatohepatitis22Colorectal cancer20Non-alcoholic steatohepatitis17Chronic hepatitis B16Hepatitis D14Primary biliary cholangitis14Cholangitis sclerosing12Endometrial cancer12Non-small cell lung cancer12Alpha-1 antitrypsin deficiency11Gastric cancer11Malignant melanoma11Biliary neoplasm10Hepatitis B10Breast cancer9Ovarian cancer9Bile duct cancer8Gallbladder cancer8Hepatic cancer8Pancreatic carcinoma8Adenocarcinoma pancreas7+215

Clinical trials in Hepatobiliary disorders

357 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

357 clinical trials

Cholangiocarcinoma

Not recruiting

Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Fondation Franc.Cancerologie Digestive

Chronic hepatitis C

Not recruiting

Comparing bemnifosbuvir-ruzasvir and sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in adult patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruzasvir
  • Sponsor:Atea Pharmaceuticals Inc.

Hepatic cirrhosis+2

Not recruiting

Study of VS-01 with different treatment times compared to standard care alone in patients with overt hepatic encephalopathy and liver cirrhosis complications

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Citric Acid, Anhydrous Ph. Eur.
  • Sponsor:Versantis AG

Gastric cancer+3

Not recruiting

Study of AZD4360 safety and effectiveness in adults with advanced solid tumors including gastric, gastroesophageal junction, biliary tract cancer and pancreatic cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:AZD4360
  • Sponsor:AstraZeneca AB

Hepatitis D

Not recruiting

Study on BJT-778 for Patients with Chronic Hepatitis Delta Infection

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Bjt-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Hepatitis D+1

Not recruiting

Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Hepatocellular carcinoma

Not recruiting

Study on the Effectiveness of NMS-01940153E, Atezolizumab, and Decitabine in Adults with Unresectable Liver Cancer Previously Treated with Other Cancer Medicines

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Nerviano Medical Sciences S.r.l.

Primary biliary cholangitis

Not recruiting

Study on the Safety and Effectiveness of Saroglitazar Magnesium for Patients with Primary Biliary Cholangitis

Investigational
Countries:IcelandIceland
  • Participants:18–64 years · 65+ years
  • Substances:SAROGLITAZAR HEMIMAGNESIUM
  • Sponsor:Zydus Therapeutics Inc.

Primary biliary cholangitis

Not recruiting

Study on the Long-Term Safety of Obeticholic Acid and Bezafibrate for Patients with Primary Biliary Cholangitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bezafibrate
  • Sponsor:Intercept Pharmaceuticals Inc.

Hepatitis B

Not recruiting

Study on Bepirovirsen for Patients with HIV and Chronic Hepatitis B on Antiretroviral Treatment

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Substances studied in this area

The therapies tested most often in Hepatobiliary disorders trials.

Durvalumab37 clinical trialsBevacizumab29 clinical trialsAtezolizumab27 clinical trialsCisplatin26 clinical trialsLenvatinib22 clinical trialsTremelimumab22 clinical trialsGemcitabine20 clinical trialsInfliximab15 clinical trialsMycophenolate Mofetil15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.